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Background: There have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter 
duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation.
Methods: We randomly assigned 2,117 patients with coronary artery stenosis into two groups according to DAPT duration and stent type; 3-month 
DAPT following Endeavor zotarolimus-eluting stent (E-ZES) implantation (n=1,059) vs. 12-month DAPT following the other DES implantation 
(n=1,058). We hypothesized that the 3-month DAPT group would be non-inferior to the 12-month group for the primary composite endpoint 
(cardiovascular death, myocardial infarction, stent thrombosis, target-vessel revascularization, or bleeding) at 1 year.
Results: The primary end point occurred in 37 (5.2%) patients assigned to E-ZES (3-month DAPT) compared with 37 (5.3%) patients assigned 
to the other DES (12-month DAPT) (difference -0.1%; 95% CI -2.9~2.7; P=0.95; P=0.002 for non-inferiority). The composite rates of any death, 
myocardial infarction, or stent thrombosis were 0.8% and 1.1%, respectively (95% CI, -1.1~0.7; P=0.65). The rates of stent thrombosis were 0.2% 
and 0.3%, respectively (95% CI -0.6~0.3; P=0.66) without its further occurrence after cessation of clopidogrel in 3-month DAPT group.
Conclusions: Three-month DAPT after E-ZES implantation was non-inferior to 12-month DAPT after the other DESs implantation with respect to the 
occurrence of primary end point.
Variables
3 month DAPT
(n=1,059)
12 month DAPT
(n=1,058)
Difference
(95% CI)
p
Composite events
Primary endpoint, no. (%) 37 (5.2) 37 (5.3) -0.1% (-2.9 ~ 2.7) 0.95
Death from any cause, myocardial infarction, or stent thrombosis, no. 
(%)
8 (0.8) 10 (1.1) -0.3% (-1.1 ~ 0.7) 0.65
Death from cardiovascular cause or myocardial infarction, no. (%) 4 (0.4) 7 (0.7) -0.3% (-1.0 ~ 0.4) 0.37
Each components
Death, no. (%)
From any cause 5 (0.5) 7 (0.7) -0.2% (-0.9 ~ 0.5) 0.57
From cardiovascular cause 2 (0.2) 4 (0.4) -0.2% (-0.7 ~ 0.3) 0.41
Myocardial infarction, no. (%) 2 (0.2) 4 (0.4) -0.2% (-0.7 ~ 0.3) 0.42
Target-vessel revascularization, no. (%) 27 (4.0) 24 (4.0) 0.0% (-2.7 ~ 2.6) 0.63
Non-target vessel revascularization, no. (%) 10 (1.8) 7 (1.0) 0.8% (-0.5 ~ 2.1) 0.42
Stent thrombosis, definite or probable, no. (%) 2 (0.2) 3 (0.3) -0.1% (-0.6 ~ 0.3) 0.66
< 1months 2 0
1-3 months 0 0
3-12 months 0 3
Bleeding, no. (%)
Major or minor 5 (0.6) 9 (0.9) -0.3% (-1.1 ~ 0.4) 0.29
Major 2 (0.2) 5 (0.5) -0.3% (-0.8 ~ 0.2) 0.26
Cerebrovascular accidents, no. (%) 6 (1.1) 6 (2.5) -1.4% (-4.8 ~ 2.0) 0.98
